By understanding second-life applications for BEV batteries, OEMs can reduce cost of ownership, improve maintainability, and ...

Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...

BMS has set a list price of $6,164 for a 30-day supply of the new drug, which is around 42% higher than the $4,344 Amgen charges wholesalers for a 30-day supply of Otezla, ahead of any discounts ...

Battery-electric vehicles are already playing a crucial role in advancing fossil-free mobility. However, significant ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

SK On will present its expanded battery portfolio at InterBattery 2025 in Seoul at the beginning of March, including a model ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

No other corporate actions details are available.

A new study from Mass General Brigham researchers has found faster accumulation of tau—a key indicator of Alzheimer’s disease—in the brains of women over the age of 70 who took menopausal hormone ...